Profile data is unavailable for this security.
About the company
EyePoint Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing and commercializing innovative therapeutics to help improve the lives of patients with serious retinal diseases. The Company’s lead product candidate, DURAVYU, is an investigational sustained delivery treatment for anti-vascular endothelial growth factor (anti-VEGF) mediated retinal diseases combining vorolanib, a selective and patent-protected tyrosine kinase inhibitor with Durasert E. DURAVYU is presently in Phase 3 global, pivotal clinical trials for wet age-related macular degeneration (wet AMD). Additional pipeline programs include EYP-2301, a promising TIE-2 agonist, razuprotafib, formulated in Durasert E to potentially improve outcomes in serious retinal diseases. The Company’s other products include YUTIQ and DEXYCU.
- Revenue in USD (TTM)56.04m
- Net income in USD-146.78m
- Incorporated2008
- Employees165.00
- LocationEyePoint Pharmaceuticals Inc480 Pleasant Street, Suite C400WATERTOWN 02472United StatesUSA
- Phone+1 (617) 926-5000
- Fax+1 (617) 926-5050
- Websitehttps://eyepointpharma.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Precigen Inc | 4.20m | -156.65m | 475.24m | 143.00 | -- | -- | -- | 113.13 | -0.5714 | -0.5714 | 0.0151 | 0.0524 | 0.0319 | -- | 5.18 | 29,377.62 | -118.84 | -38.49 | -148.57 | -47.33 | -2.17 | 49.53 | -3,728.87 | -334.29 | -- | -- | 0.00 | -- | -36.95 | -46.64 | -31.63 | -- | -25.69 | -- |
| SIGA Technologies Inc | 120.33m | 48.53m | 477.23m | 46.00 | 9.92 | 2.21 | 9.73 | 3.97 | 0.6736 | 0.6736 | 1.68 | 3.03 | 0.4909 | 0.4597 | 9.51 | 2,615,876.00 | 19.80 | 27.72 | 25.04 | 33.36 | 76.55 | 86.06 | 40.33 | 44.28 | 6.28 | -- | 0.00 | 37.70 | -0.8561 | 38.99 | -13.01 | -- | 7.85 | -- |
| Tilray Brands Inc | 826.66m | -945.69m | 497.59m | 2.65k | -- | 0.1731 | -- | 0.6019 | -1.05 | -1.05 | 0.9603 | 2.80 | 0.2171 | 2.25 | 8.57 | 311,945.70 | -24.39 | -- | -26.28 | -- | 30.88 | -- | -112.36 | -- | 1.61 | -0.8888 | 0.1069 | -- | 25.80 | -- | 83.14 | -- | -- | -- |
| Zevra Therapeutics Inc | 40.59m | -91.99m | 514.54m | 59.00 | -- | 12.54 | -- | 12.68 | -1.90 | -1.90 | 0.823 | 0.7503 | 0.2506 | -- | 3.88 | 687,932.20 | -56.78 | -37.95 | -68.88 | -48.83 | 84.42 | -- | -226.64 | -193.51 | 2.93 | -10.59 | 0.5943 | -- | -14.02 | 12.96 | -129.13 | -- | 196.92 | -- |
| ASP Isotopes Inc | 4.41m | -36.61m | 536.79m | 136.00 | -- | 11.92 | -- | 121.85 | -0.6144 | -0.6144 | 0.0712 | 0.5899 | 0.0647 | -- | 8.42 | 32,393.31 | -49.79 | -- | -58.98 | -- | 37.40 | -- | -769.93 | -- | 7.17 | -5.24 | 0.4493 | -- | 857.03 | -- | -115.60 | -- | -- | -- |
| Theravance Biopharma Inc | 65.27m | -58.33m | 552.51m | 97.00 | -- | 3.33 | -- | 8.47 | -1.19 | -1.19 | 1.33 | 3.32 | 0.1826 | -- | 4.35 | 672,845.40 | -16.32 | -34.51 | -17.63 | -40.08 | -- | -- | -89.38 | -254.51 | -- | -- | 0.1573 | -- | 12.12 | -2.59 | -2.22 | -- | -36.34 | -- |
| Evolus Inc | 275.46m | -56.20m | 593.82m | 372.00 | -- | -- | -- | 2.16 | -0.8883 | -0.8883 | 4.36 | -0.1025 | 1.25 | 8.14 | 6.74 | 829,707.80 | -25.57 | -37.04 | -33.40 | -57.14 | 68.14 | 65.19 | -20.40 | -51.26 | 2.16 | -2.20 | 1.06 | -- | 31.76 | 50.12 | 18.26 | -- | 1.10 | -- |
| Phathom Pharmaceuticals Inc | 81.86m | -345.79m | 622.04m | 427.00 | -- | -- | -- | 7.60 | -5.24 | -5.24 | 1.23 | -4.86 | 0.2516 | 4.88 | 4.07 | 191,707.30 | -106.28 | -72.89 | -129.70 | -84.11 | 86.23 | -- | -422.42 | -1,799.61 | 3.54 | -4.82 | 2.50 | -- | 8,001.47 | -- | -65.84 | -- | 0.4505 | -- |
| Sinovac Biotech Ltd | 429.20m | -130.73m | 639.90m | 3.04k | -- | -- | -- | 1.49 | -1.31 | -1.31 | 4.31 | 86.81 | 0.0322 | 0.2019 | 1.08 | 141,325.00 | -2.23 | 36.14 | -3.30 | 58.37 | 92.09 | 90.77 | -69.19 | 65.87 | 11.24 | -- | 0.0262 | -- | -69.97 | 14.31 | -198.16 | -- | 91.80 | -- |
| Elite Pharmaceuticals Inc | 70.00m | -17.99m | 640.90m | 64.00 | -- | 17.58 | -- | 9.16 | -0.0167 | -0.0167 | 0.0659 | 0.0341 | 0.8461 | 2.27 | 4.06 | 1,093,699.00 | -21.74 | 19.07 | -27.33 | 24.29 | 44.16 | 46.63 | -25.70 | 20.77 | 1.90 | 0.4235 | 0.1988 | 0.00 | 65.79 | 49.55 | 464.56 | -- | 111.50 | -- |
| Eyepoint Pharmaceuticals Inc | 56.04m | -146.78m | 664.72m | 165.00 | -- | 2.23 | -- | 11.86 | -2.41 | -2.41 | 0.9262 | 4.34 | 0.162 | 1.18 | 32.42 | 339,648.50 | -42.43 | -35.88 | -49.96 | -42.05 | 93.29 | 84.82 | -261.91 | -201.78 | 7.79 | -- | 0.00 | -- | -5.97 | 16.27 | -84.86 | -- | 80.24 | -- |
| Nika Pharmaceuticals Inc | 160.00 | -88.57k | 708.22m | -- | -- | -- | -- | 4,426,376.00 | -0.00008 | -0.00008 | 0.00 | -0.0002 | 0.0042 | -- | -- | -- | -231.68 | -21,428.06 | -- | -- | -- | -- | -55,356.25 | -- | -- | -- | 7.69 | -- | -- | -- | -47.74 | -- | -- | -- |
| Xeris Biopharma Holdings Inc | 222.55m | -45.08m | 757.53m | 394.00 | -- | -- | -- | 3.40 | -0.3015 | -0.3015 | 1.49 | -0.2252 | 0.6826 | 0.8462 | 5.32 | 564,850.30 | -13.83 | -31.61 | -18.63 | -42.28 | 82.21 | 79.76 | -20.25 | -77.77 | 1.17 | -0.8589 | 1.18 | -- | 23.89 | 136.89 | 11.92 | -- | -4.75 | -- |
| Avadel Pharmaceuticals PLC (ADR) | 194.45m | -26.41m | 853.69m | 188.00 | -- | 11.49 | -- | 4.39 | -0.2743 | -0.2743 | 2.02 | 0.7665 | 1.16 | 1.20 | 6.05 | 1,034,309.00 | -15.73 | -42.00 | -22.28 | -50.53 | 90.06 | -- | -13.58 | -194.15 | 2.33 | -1.85 | 0.00 | -- | 504.79 | 23.35 | 69.53 | -- | -- | -- |
| CorMedix Inc | 82.55m | 17.18m | 861.32m | 64.00 | 51.44 | 6.83 | 48.86 | 10.43 | 0.2253 | 0.2253 | 1.34 | 1.70 | 0.7587 | 0.8093 | -- | 1,289,904.00 | 15.79 | -42.85 | 19.78 | -49.82 | 95.19 | 91.93 | 20.81 | -327.99 | 3.99 | -- | 0.00 | -- | -- | 173.65 | 61.31 | -- | 25.91 | -- |
Data as of Jul 03 2025. Currency figures normalised to EyePoint Pharmaceuticals Inc's reporting currency: US Dollar USD
65.70%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Cormorant Asset Management LPas of 31 Mar 2025 | 8.33m | 12.20% |
| Suvretta Capital Management LLCas of 31 Mar 2025 | 6.80m | 9.97% |
| Adage Capital Management LPas of 31 Mar 2025 | 6.20m | 9.08% |
| BlackRock Fund Advisorsas of 31 Mar 2025 | 4.95m | 7.25% |
| Franklin Advisers, Inc.as of 31 Mar 2025 | 4.15m | 6.08% |
| Federated Global Investment Management Corp.as of 31 Mar 2025 | 3.71m | 5.44% |
| The Vanguard Group, Inc.as of 31 Mar 2025 | 3.71m | 5.43% |
| RA Capital Management LPas of 31 Mar 2025 | 3.18m | 4.66% |
| Citadel Advisors LLCas of 31 Mar 2025 | 2.23m | 3.26% |
| SSgA Funds Management, Inc.as of 31 Mar 2025 | 1.59m | 2.33% |
More ▼
Data from 31 Mar 2025 - 31 Mar 2025Source: FactSet Research Systems Inc.
